Slides - Clinical Trial Results .org

More documents

Recommendations

Info

<strong>Results</strong>: ITT Cohort Selected Safety Endpoints GIK (n=411) Placebo (n=460) P value Serious Adverse Events 7% 9% 0.26 Heart Failure 2% 3% 0.47 All Participants Any K+ > 5.5 mEq/L 4% 2% 0.10 Any K+ < 3.5 mEq/L 25% 30% 0.10 Any glucose >300 mg/dL 21% 10% < 0.001 Participants with Diabetes Any glucose >300 mg/dL 44% 29% 0.02 Participants without Diabetes Any glucose >300 mg/dL 11% 3% < 0.001
Limitations • Primary endpoint progression to MI was not significantly different between groups -- favorable results based on prespecified major secondary endpoints, biologically consistent with the GIK benefit seen in pre-clinical studies • Absolute numbers of clinical endpoints were relatively small • Reduction in infarct size results, although consistent with experimental studies of early GIK, based on the relatively small biological mechanism cohort • Understanding of the long-term effects of GIK on HF and mortality will require longer follow-up, underway
Page 1 and 2: Results of the IMMEDIATE (Immediate
Page 3 and 4: Carl Apstein, MD, FACC The IMMEDIAT
Page 5 and 6: Background: Rationale for Placebo-C
Page 7 and 8: Methods: Basic Features of Study De
Page 9 and 10: Methods: Pre-Specified Endpoints
Page 11 and 12: Methods: Exclusion Criteria • HF
Page 13 and 14: Methods: Analysis • Sample size c
Page 15 and 16: Results: Screening and Enrollment o
Page 17 and 18: Results: Time from Ischemic Symptom
Page 19 and 20: Results: ITT Cohort Hospital and 30
Page 21 and 22: Results: ITT Cohort Hospital and 30
Page 23 and 24: Results: Cohort Presenting with ST
Page 25 and 26: Results: Cohort Presenting with ST
Page 27 and 28: Median infarct size (IQR) Results:
Page 29: Median infarct size (IQR) Results:
Page 33 and 34: James Atkins • Assaad Sayah • M

Slides - Clinical Trial Results .org

Create successful ePaper yourself

Delete template?

Save as template?